Abstract
Therapies that are believed to target the underlying mechanisms of Alzheimers disease have now reached human clinical trials, with the number of agents in late stage development having increased dramatically in recent years. Primary targets include beta-amyloid, whose presence and accumulation in the brain is thought to contribute to the development of Alzheimers disease, and tau protein which, when hyperphosphorylated, results in the formation of neurofibrillary tangles of paired helical filaments, also believed to be involved in the pathogenesis of Alzheimers disease. In the review, the current status of Alzheimers Disease therapies under study is discussed, including the scientific basis for each strategy.
Keywords: Alzheimer's disease, clincal trials, drug development for Alzheimer's disease, mild cognitive impairment
Reviews on Recent Clinical Trials
Title: The Pulse of Drug Development for Alzheimers Disease
Volume: 5 Issue: 1
Author(s): Michael S. Rafii
Affiliation:
Keywords: Alzheimer's disease, clincal trials, drug development for Alzheimer's disease, mild cognitive impairment
Abstract: Therapies that are believed to target the underlying mechanisms of Alzheimers disease have now reached human clinical trials, with the number of agents in late stage development having increased dramatically in recent years. Primary targets include beta-amyloid, whose presence and accumulation in the brain is thought to contribute to the development of Alzheimers disease, and tau protein which, when hyperphosphorylated, results in the formation of neurofibrillary tangles of paired helical filaments, also believed to be involved in the pathogenesis of Alzheimers disease. In the review, the current status of Alzheimers Disease therapies under study is discussed, including the scientific basis for each strategy.
Export Options
About this article
Cite this article as:
Rafii S. Michael, The Pulse of Drug Development for Alzheimers Disease, Reviews on Recent Clinical Trials 2010; 5 (1) . https://dx.doi.org/10.2174/157488710790820490
DOI https://dx.doi.org/10.2174/157488710790820490 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ATP-Binding Cassette Transporters in Inflammatory Brain Disease
Current Pharmaceutical Design Disease Progression in HIV Late Presenters: the Role of HIV Clinical Indicator Diseases Prior to HIV Diagnosis
Current HIV Research Targeting Protozoan Parasite Metabolism: Glycolytic Enzymes in the Therapeutic Crosshairs
Current Medicinal Chemistry Predicting the Potential Public Health Impact of Disease-Modifying HIV Vaccines in South Africa: The Problem of Subtypes
Current Drug Targets - Infectious Disorders Ribosome-inactivating Proteins from Root Tubers and Seeds of Trichosan-thes kirilowii and Other Trichosanthes Species
Protein & Peptide Letters An Ion Channel Chip for Diagnosis and Prognosis of Autoimmune Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Inflammation in Epilepsy
Current Pediatric Reviews The Effect of Pharmacotherapy for Attention Deficit Hyperactivity Disorder on Risk of Seizures in Pediatric Patients as Assessed in an Insurance Claims Database
Current Drug Safety Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy The Changing Face of Cytokines in the Brain: Perspectives From EAE
Current Pharmaceutical Design Synthetic and Natural Protease Inhibitors Provide Insights into Parasite Development, Virulence and Pathogenesis
Current Medicinal Chemistry Viral Product Trafficking to Mitochondria, Mechanisms and Roles in Pathogenesis
Infectious Disorders - Drug Targets Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets Genomic Databases and the Search of Protein Targets for Protozoan Parasites
Current Drug Targets PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Endocrine, Metabolic & Immune Disorders - Drug Targets Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis
Current HIV Research Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Caveolin-1: A Promising Therapeutic Target for Diverse Diseases
Current Molecular Pharmacology The Efficacy of Viral Capsid Inhibitors in Human Enterovirus Infection and Associated Diseases
Current Medicinal Chemistry